MINERVA IMAGING
LIVE

Serial Number

79418919

Owner

Minerva Imaging ApS

Attorney

David M. Janet

Filing Date

Feb 3, 2025

Add to watchlist:

No watchlists yet
View on USPTO

MINERVA IMAGING Trademark

Serial Number: 79418919

MINERVA IMAGING is a trademark filed by Minerva Imaging ApS on February 3, 2025. The trademark is classified under Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Minerva Imaging ApS

LyshĂžjvej 21

Entity Type: 16

Trademark Details

Filing Date

February 3, 2025

Registration Date

Not Registered

Goods & Services

Pharmaceutical drug development services in the fields of cancer, cardiovascular disease, and cell therapy, including stem cell therapy; research of pharmaceuticals to treat cancer, cardiovascular disease, and cell therapy, including stem cell therapy; research relating to cancer, cardiovascular disease, and cell therapy, including stem cell therapy; pharmaceutical research and development related to cancer, cardiovascular disease, and cell therapy, including stem cell therapy; research on the subject of pharmaceuticals for cancer, cardiovascular disease, and cell therapy, including stem cell therapy; pharmaceutical research services in the fields of cancer, cardiovascular disease, and cell therapy, including stem cell therapy; clinical research and conducting clinical trials in the fields of cancer, cardiovascular disease, and cell therapy, including stem cell therapy; conducting clinical trials for pharmaceutical products in the fields of cancer, cardiovascular disease, and cell therapy, including stem cell therapy; providing medical and scientific research information in the field of pharmaceuticals and clinical trials for cancer, cardiovascular disease, and cell therapy, including stem cell therapy; providing information about the results of clinical trials for pharmaceutical products related to cancer, cardiovascular disease, and cell therapy, including stem cell therapy; pharmaceutical products development related to the treatment of cancer and cardiovascular disease; consulting services for others in the field of designing clinical trials related to cancer, cardiovascular disease, and cell therapy, including stem cell therapy; scientific and technical consulting and research services for the pharmaceutical industry in the fields of cancer, cardiovascular disease, and cell therapy, including stem cell therapy.

Custom manufacture of pharmaceuticals for the treatment of cancer.

Filing History

ASSIGNED TO EXAMINER
Jun 10, 2026 DOCK
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 19, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 19, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 19, 2026 TROA
REFUSAL PROCESSED BY IB
Sep 5, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 21, 2025 RFCS
REFUSAL PROCESSED BY MPU
Aug 21, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 18, 2025 RFCR
NON-FINAL ACTION WRITTEN
Jul 17, 2025 CNRT
ASSIGNED TO EXAMINER
Jul 14, 2025 DOCK
NEW REPRESENTATIVE AT IB RECEIVED
May 23, 2025 NREP
APPLICATION FILING RECEIPT MAILED
Mar 16, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 16, 2025 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 13, 2025 REPR